Advertisement
Organisation › Details
Cellectis (Group)
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools – meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors. To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending. Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over €70 million in funding since inception. *
Start | 1999-01-01 established | |
Today | Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS) | |
Industry | genome editing (gene editing) | |
Industry 2 | TALEN® technology (Transcription Activator-Like Effector Nuclease) | |
Person | Choulika, André (Cellectis 200701 CEO + Co-Founder) | |
Person 2 | Dutang, Eric (Cellectis 2016– CFO joined 201505) | |
Region | Romainville | |
Country | France | |
Street | 8 Rue de la Croix Jarry | |
City | 75013 Paris | |
Tel | +33-1-8169-1600 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | D: 101 to 500 (2019-12-31) |
Currency | USD | |
Annual sales | 22,990,000 (income, total, consolidated (2019) 2019-12-31) | |
Profit | -115,212,000 (2019-12-31) | |
Cash | 340,522,000 (2019-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Cellectis (Group)
- [1] Cellectis S.A.. (12/29/22). "Press Release: Mayflower Bioventures Launches Its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases". New York, NY....
- [2] Cellectis S.A.. (12/28/22). "Press Release: Cellectis Secures a €40 Million Credit Facility from the European Investment Bank to Support its Research, Development and Innovation Activities". Paris....
- [3] Cellectis S.A.. (2/10/22). "Press Release: Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer". New York, NY....
- [4] Metagenomi Inc.. (7/28/21). "Press Release: Metagenomi Appoints Simon Harnest as Chief Investment Officer". Emeryville, CA....
- [5] Cellectis S.A.. (2/16/21). "Press Release: Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells". Cambridge, MA & New York, NY....
- [6] Sirion Biotech GmbH. (1/7/21). "Press Release: Sirion Biotech GmbH Licensed Its LentiBoost Transduction Technology to Cellectis". Munich & Cambridge, MA....
- [7] Cellectis S.A.. (12/15/20). "Press Release: Cellectis Announces Withdrawal of Follow-On Offering". New York, NY....
- [8] Cellectis S.A.. (12/14/20). "Press Release: Cellectis Announces Launch of Follow-On Offering". New York, NY....
- [9] Cellectis S.A.. (7/6/20). "Press Release: Cellectis Reports Clinical Hold Placed on MELANI-01 Study". New York, NY....
- [10] Cellectis S.A.. (4/13/20). "Press Release: Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer". New York, NY....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top